Sabrina de Souza

Sabrina de Souza

Auto-generated profile, based on publicly available information

Sabrina de Souza

Department of Physiology, Michigan State University, East Lansing, MI, United States

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2026 in Science Immunology
Verified
Journal Article
Closed access
JSJaewon Sim
Jaewon Sim
EOElizabeth O’GUin
Elizabeth O’GUin
CSChiho Sugimoto
Chiho Sugimoto
SLSophie Laumet
Sophie Laumet
KMKarli Monahan
Karli Monahan
Geoffroy LaumetGeoffroy Laumet
Geoffroy Laumet
Women frequently experience longer-lasting pain than men, indicating delayed pain resolution, but the mechanisms underlying this sex difference remain unclear. Here, we show that interleukin-10 + (IL-10 + ) monocytes resolve inflammatory pain by signaling to IL-10R1 + sensory neurons in a mouse model of skin inflammation. Male mice exhibited faster pain resolution than females, which was associated with higher numbers of IL-10 + monocytes. In both sexes, pain resolution was impaired by deleting Il10 from monocytes or Il10ra from sensory neurons. Androgen signaling promoted IL-10 production by monocytes, driving sex differences in IL-10 + monocyte abundance. Enhancing IL-10 + monocytes with resolvin D1 accelerated pain resolution in both sexes. In humans, pain resolved faster in men than in women after traumatic injury and was associated with higher circulating monocytes and IL-10 levels in men. These findings identify a role for peripheral IL-10 + monocytes in sex-specific pain resolution and highlight immune mechanisms that may prevent chronic pain.

4 March 2025 in Pain
Verified
Journal Article
Closed access
SSSabrina de Souza
Sabrina de Souza
SLSophie Laumet
Sophie Laumet
HHHannah Hua
Hannah Hua
KIKufreobong E. Inyang
Kufreobong E. Inyang
JSJaewon Sim
Jaewon Sim
Geoffroy LaumetGeoffroy Laumet
Geoffroy Laumet
Immune cells play a critical role in the transition from acute to chronic pain. However, the role of mast cells in pain remains underinvestigated. Here, we demonstrated that the resolution of inflammatory pain is markedly delayed in mast cell–deficient mice. In response to complete Freund adjuvant, mast cell–deficient mice showed greater levels of nitric oxide, leukocyte infiltration, and altered cytokine/chemokine profile in inflamed skin in both sexes. In wild-type mice, the number of mast cell and mast cell–derived chymases, chymase 1 (CMA1) and mast cell protease 4 (MCPT4), increased in the inflamed skin. Inhibiting chymase enzymatic activity delayed the resolution of inflammatory pain. Consistently, local pharmacological administration of recombinant CMA1 and MCPT4 promoted the resolution of pain hypersensitivity and attenuated the upregulation of cytokines and chemokines under inflammation. We identified CCL9 as a target of MCPT4. Inhibition of CCL9 promoted recruitment of CD206+ myeloid cells and alleviated inflammatory pain. Our work reveals a new role of mast cell–derived chymases in preventing the transition from acute to chronic pain and suggests new therapeutic avenues for the treatment of inflammatory pain.

7 August 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
SSSabrina de Souza
Sabrina de Souza
SLSophie Laumet
Sophie Laumet
KIKufreobong E. Inyang
Kufreobong E. Inyang
HHHannah Hua
Hannah Hua
JSJaewon Sim
Jaewon Sim
Geoffroy LaumetGeoffroy Laumet
Geoffroy Laumet
Immune cells play a critical role in the transition from acute to chronic pain. However, the role of mast cells in pain remains under-investigated. Here, we demonstrated that the resolution of inflammatory pain is markedly delayed in mast-cell-deficient mice. In response to Complete Freund Adjuvant (CFA), mast-cell-deficient mice showed greater levels of nitric oxide and altered cytokine/chemokine profile in inflamed skin in both sexes. In Wild-Type (WT) mice, the number of mast cell and mast cell-derived chymases; chymase 1 (CMA1) and mast cell protease 4 (MCPT4) increased in the inflamed skin. Inhibiting chymase enzymatic activity delayed the resolution of inflammatory pain. Consistently, local pharmacological administration of recombinant CMA1 and MCPT4 promoted the resolution of pain hypersensitivity and attenuated the upregulation of cytokines and chemokines under inflammation. We identified CCL9 as a target of MCPT4. Inhibition of CCL9 promoted recruitment of CD206 + myeloid cells and alleviated inflammatory pain. Our work reveals a new role of mast cell-derived chymases in preventing the transition from acute to chronic pain and suggests new therapeutic avenues for the treatment of inflammatory pain. Summary: Mast cell-derived chymases play an unexpected role in the resolution of inflammatory pain and regulate the immune response. Graphical Mast cells derived chymase MCPT4 degrades CCL9 to promote acute inflammatory pain resolution and prevent chronic pain.: CFA-induced inflammation increases mast cells that degranulate and release chymases, like MCPT4 and CMA1, which in turn cleaves cytokines and chemokines such as CCL9. CCL9 cleavage induces the recruitment of CD206 + myeloid cells to promote the resolution of pain and prevent the transition from acute to chronic pain.

27 February 2026 in Pain
Verified
Journal Article
Closed access
SSSabrina de Souza
Sabrina de Souza
HHHannah Hua
Hannah Hua
SLSophie Laumet
Sophie Laumet
JSJaewon Sim
Jaewon Sim
CVCharlotte Vanacker
Charlotte Vanacker
Geoffroy LaumetGeoffroy Laumet
Geoffroy Laumet
The development of persistent postoperative pain remains a major clinical challenge, partly because of limited understanding of the molecular mediators driving inflammation and pain after surgery. The interaction between the nervous and immune systems plays a critical role in the initiation and maintenance of pain, but immune mediators in this process remain poorly characterized. Targeting cytokines and chemokines represents an attractive strategy to regulate inflammation in both the peripheral and central nervous systems and to modulate pain. Here, we demonstrated that the understudied chemokine C–C motif chemokine ligand 12 (CCL12) is significantly elevated in surgically incised skin. Administration of recombinant CCL12 induced dose-dependent mechanical and thermal hypersensitivity in naïve mice. C–C motif chemokine ligand 12 acted directly on nociceptors to increase calcium influx and neuronal excitability in dissociated dorsal root ganglia neurons. Notably, neutralization of CCL12 reduced pain behaviors and prevented the development of hyperalgesic priming. Surprisingly, CCL12 did not modulate the immune response to incision. These findings suggest that CCL12 is a key mediator of postoperative pain and highlights its potential as a therapeutic target for improving pain management after surgery.